Noradrenalina Kabi (Noradrenaline Tartrate)

Noradrenalina Kabi is used as a vasopressor to manage critical circulatory failure.

• Hypotension: Restores arterial pressure in patients with severe low blood pressure unresponsive to fluid therapy.
• Septic shock: Improves systemic vascular resistance and organ perfusion during severe infection‑induced circulatory collapse.
• Cardiac arrest: Provides immediate vasoconstriction to support coronary and cerebral perfusion during resuscitation efforts.

• Noradrenaline tartrate acts as a direct agonist at alpha‑adrenergic receptors, primarily α1, on vascular smooth muscle. Stimulation of these receptors induces potent vasoconstriction, increasing systemic vascular resistance and arterial blood pressure. The drug also exhibits modest β1 activity, supporting cardiac output, which together help reverse hypotensive states in critical care settings.

Adverse reactions to Noradrenalina Kabi may vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often related to rapid blood pressure changes.
• Tachycardia: increased heart rate due to β1 stimulation.
• Peripheral ischemia: reduced blood flow causing cold extremities.
• Nausea: occasional gastrointestinal discomfort.

Serious or Rare Side Effects

• Cardiac arrhythmias: potentially life‑threatening rhythm disturbances.
• Severe hypertension: abrupt excessive rise in blood pressure.
• Tissue necrosis: local injury at infusion site if extravasation occurs.

When using Noradrenalina Kabi, clinicians should observe several safety measures.

• Dose titration: adjust infusion rate based on continuous blood pressure monitoring.
• Cardiac monitoring: observe for arrhythmias and ischemic changes during therapy.
• Peripheral perfusion: assess limb circulation regularly to detect early signs of ischemia.
• Drug compatibility: avoid mixing with solutions that may precipitate or inactivate the catecholamine.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Noradrenalina Kabi can interact with other agents that affect cardiovascular tone or catecholamine metabolism.

Major Interactions (Avoid)

• MAO inhibitors: concurrent use may cause hypertensive crisis.
• β‑blockers: may blunt the desired pressor response and increase risk of bradycardia.

Moderate Interactions (Monitor Closely)

• Calcium channel blockers: can potentiate hypotensive effects if withdrawn abruptly.
• Diuretics: may enhance volume depletion, requiring careful fluid management.
• Other vasopressors: combined use may lead to excessive vasoconstriction and organ ischemia.